JP6470170B2 - 改変抗体領域およびその使用 - Google Patents

改変抗体領域およびその使用 Download PDF

Info

Publication number: JP6470170B2
Authority: JP; Japan
Prior art keywords: region; antibody; modified; polypeptide; parent
Prior art date: 2012-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2015509206A

Other languages

English (en)

Japanese (ja)

Other versions

JP2015515497A (ja

JP2015515497A5 (2

Inventor

ショート、ジェイ、エム．

チャン、ファイ、ウェン

フレイ、ガーハード

Original Assignee

バイオアトラ、エルエルシー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2013-04-26

Publication date

2019-02-13

2013-04-26 Application filed by バイオアトラ、エルエルシー filed Critical バイオアトラ、エルエルシー

2015-05-28 Publication of JP2015515497A publication Critical patent/JP2015515497A/ja

2016-10-13 Publication of JP2015515497A5 publication Critical patent/JP2015515497A5/ja

2019-02-13 Application granted granted Critical

2019-02-13 Publication of JP6470170B2 publication Critical patent/JP6470170B2/ja

Status Active legal-status Critical Current

2033-04-26 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP2015509206A 2012-04-27 2013-04-26 改変抗体領域およびその使用 Active JP6470170B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261639729P	2012-04-27	2012-04-27
US61/639,729		2012-04-27
PCT/US2013/038538 WO2013163630A1 (en)	2012-04-27	2013-04-26	Modified antibody regions and uses thereof

Publications (3)

Publication Number	Publication Date
JP2015515497A JP2015515497A (ja)	2015-05-28
JP2015515497A5 JP2015515497A5 (2)	2016-10-13
JP6470170B2 true JP6470170B2 (ja)	2019-02-13

Family

ID=49483948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015509206A Active JP6470170B2 (ja)	2012-04-27	2013-04-26	改変抗体領域およびその使用

Country Status (13)

Country	Link
US (2)	US20150065690A1 (2)
EP (2)	EP2841458A4 (2)
JP (1)	JP6470170B2 (2)
KR (2)	KR20150008082A (2)
CN (1)	CN104428317B (2)
AU (3)	AU2013251309B2 (2)
BR (1)	BR112014026740B1 (2)
CA (1)	CA2871807C (2)
HK (1)	HK1207654A1 (2)
IN (1)	IN2014DN08721A (2)
MX (2)	MX360368B (2)
RU (1)	RU2014147741A (2)
WO (1)	WO2013163630A1 (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2947605A1 (en) *	2014-05-13	2015-11-19	Bioatla, Llc	Conditionally active biological proteins
FR3038517B1 (fr) *	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
US10954301B2 (en)	2015-12-14	2021-03-23	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
AU2017232546B2 (en) *	2016-03-14	2024-05-02	Universitetet I Oslo	Engineered immunoglobulins with altered FCRN binding
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3055200A1 (en)	2017-03-03	2018-09-07	Obsidian Therapeutics, Inc.	Compositions and methods for immunotherapy
KR102746901B1 (ko)	2017-03-03	2024-12-26	옵시디안 테라퓨틱스, 인크.	Cd19 조성물 및 면역요법을 위한 방법
WO2019241315A1 (en)	2018-06-12	2019-12-19	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en)	2018-10-24	2020-04-30	Obsidian Therapeutics, Inc.	Er tunable protein regulation
KR102521276B1 (ko) *	2018-10-31	2023-04-12	바이오아트라, 인코퍼레이티드	항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도
US11542333B2 (en) *	2019-01-03	2023-01-03	Invetx, Inc.	Compositions for increasing half-life of a therapeutic agent in canines and methods of use
KR20210149251A (ko)	2019-03-08	2021-12-08	옵시디안 테라퓨틱스, 인크.	조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020227515A1 (en)	2019-05-07	2020-11-12	Voyager Therapeutics, Inc.	Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP4014050A1 (en)	2019-08-12	2022-06-22	Voyager Therapeutics, Inc.	High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en)	2019-08-30	2023-03-23	Obsidian Therapeutics, Inc.	Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en)	2019-09-06	2021-03-11	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
EP4225787A4 (en) *	2020-05-21	2024-10-23	Zydus Lifesciences Limited	FC VARIANT AND PRODUCTION THEREOF
JP2023526540A (ja)	2020-05-22	2023-06-21	フォーマイコンアーゲー	Ａｃｅ２融合タンパク質及びその使用方法
MX2023004933A (es)	2020-10-29	2023-06-06	Formycon Ag	Proteinas de fusion de ace2 y usos de las mismas.
EP4301333A2 (en)	2021-03-03	2024-01-10	Formycon AG	Formulations of ace2 fc fusion proteins
US20250027067A1 (en)	2021-11-24	2025-01-23	Formycon Ag	Improved ace2 fusion proteins
WO2023094571A1 (en)	2021-11-25	2023-06-01	Formycon Ag	Stabilization of ace2 fusion proteins
EP4386084A1 (en)	2022-12-14	2024-06-19	Formycon AG	Improved ace2 fusion proteins
WO2026039779A1 (en)	2024-08-15	2026-02-19	Yale University	Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7361740B2 (en) *	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60334141D1 (de) *	2002-10-15	2010-10-21	Facet Biotech Corp	VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
WO2004041854A2 (en)	2002-11-05	2004-05-21	Affinium Pharmaceuticals, Inc.	Essential novel bacterial polypeptides
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) *	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
JP2007531707A (ja)	2003-10-15	2007-11-08	ピーディーエルバイオファーマ，インコーポレイテッド	ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
WO2005047327A2 (en) *	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) *	2004-07-12	2013-05-29	马克罗基因公司	具有变异Fc区的抗体的鉴定和工程化以及使用方法
CN103172731A (zh) *	2004-07-15	2013-06-26	赞科股份有限公司	优化的Fc变体
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
DK1817340T3 (da)	2004-11-12	2012-08-13	Xencor Inc	Fc-varianter med ændret binding til fcrn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
WO2006105062A2 (en) *	2005-03-29	2006-10-05	Verenium Corporation	Altered antibody fc regions and uses thereof
HUE029465T2 (en) *	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
KR20080073293A (ko) *	2005-10-14	2008-08-08	메디뮨 엘엘씨	항체 라이브러리의 세포 디스플레이
RU2529951C2 (ru) *	2007-12-26	2014-10-10	Ксенкор, Инк.	ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
ES2675730T3 (es) *	2008-06-04	2018-07-12	Macrogenics, Inc.	Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
EP2389192A4 (en)	2009-01-23	2013-01-16	Biogen Idec Inc	STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
JP5816170B2 (ja)	2009-06-26	2015-11-18	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
TWI667346B (zh)	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的FcRn親和力之抗體
US8735546B2 (en) *	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en)	2010-08-17	2013-07-09	Qualcomm Incorporated	Systems and methods for traffic policing
BR112014000524B1 (pt)	2011-07-15	2020-06-23	Basell Poliolefine Italia S.R.L.	Cinta de poliolefina compreendendo um copolímero aleatório de propileno com 1-hexeno
RU2732151C2 (ru) *	2011-09-30	2020-09-11	Чугаи Сейяку Кабусики Кайся	Библиотека зависимых от концентрации ионов связывающих молекул
AU2012366290A1 (en) *	2012-01-19	2014-08-07	Therapeutic Proteins International, LLC	Stabilization of the anti-CD20 antibody Rituximab

2013
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
- 2013-04-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en not_active Ceased
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active Ceased
- 2013-04-26 MX MX2018001914A patent/MX382840B/es unknown
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Ceased
- 2013-04-26 EP EP18209149.6A patent/EP3470433B1/en active Active
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active

Also Published As

Publication number	Publication date
KR20150008082A (ko)	2015-01-21
WO2013163630A1 (en)	2013-10-31
BR112014026740A2 (pt)	2017-06-27
EP3470433B1 (en)	2025-12-03
MX2014012978A (es)	2015-02-05
US20150065690A1 (en)	2015-03-05
RU2014147741A (ru)	2016-06-20
BR112014026740B1 (pt)	2022-10-04
AU2013251309B2 (en)	2017-06-22
MX382840B (es)	2025-03-13
AU2019202229A1 (en)	2019-04-18
AU2017225111B2 (en)	2019-01-03
CN104428317A (zh)	2015-03-18
EP2841458A1 (en)	2015-03-04
BR112014026740A8 (pt)	2021-06-15
HK1207654A1 (en)	2016-02-05
AU2017225111A1 (en)	2017-09-28
US20180186863A1 (en)	2018-07-05
AU2019202229B2 (en)	2021-02-11
MX360368B (es)	2018-10-29
JP2015515497A (ja)	2015-05-28
EP2841458A4 (en)	2015-09-16
EP3470433C0 (en)	2025-12-03
AU2013251309A1 (en)	2014-10-30
CN104428317B (zh)	2018-08-28
EP3470433A1 (en)	2019-04-17
KR20200037434A (ko)	2020-04-08
CA2871807C (en)	2022-10-04
US10954288B2 (en)	2021-03-23
IN2014DN08721A (2)	2015-05-22
CA2871807A1 (en)	2013-10-31

Legal Events

Date	Code	Title	Description
2016-04-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160415
2016-04-15	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160415
2016-08-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826
2017-03-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170314
2017-05-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170519
2017-09-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170913
2017-10-03	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170914
2018-02-13	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180213
2018-06-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180608
2018-07-19	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180719
2018-07-20	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180719
2018-10-02	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002
2018-12-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181228
2018-12-28	TRDD	Decision of grant or rejection written
2019-01-08	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108
2019-01-24	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190117
2019-01-25	R150	Certificate of patent or registration of utility model	Ref document number: 6470170 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2022-01-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-01-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-01-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-01-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-01-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6470170B2 (ja)	2019-02-13	改変抗体領域およびその使用
US10894829B2 (en)	2021-01-19	Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
KR101637502B1 (ko)	2016-07-08	치료용 개 면역글로불린 및 이를 이용하는 방법
ES2758508T3 (es)	2020-05-05	Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos
KR20240093562A (ko)	2024-06-24	수의학적 용도를 위한 항-il31 항체
US12583917B2 (en)	2026-03-24	IL17A antibodies and antagonists for veterinary use
JP2022512234A (ja)	2022-02-02	補体関連疾患のための融合タンパク質構築物
CN103906764A (zh)	2014-07-02	犬源化抗体及其制备方法
HK40009281A (en)	2020-06-26	Modified antibody regions and uses thereof
HK40009281B (en)	2026-04-02	Modified antibody regions and uses thereof
US20250059295A1 (en)	2025-02-20	Steap2 directed t-cell engagers and compositions thereof
BR122024007417A2 (pt)	2024-08-27	Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula
BR122024006370A2 (pt)	2024-08-27	Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação
BR122022022755B1 (pt)	2025-11-25	Anticorpos monoclonais biespecíficos, seus usos e seu método de produção, composição farmacêutica e kit
BR112022021690B1 (pt)	2025-12-09	Anticorpos multiespecíficos, biespecíficos ou monoclonais, composição farmacêutica, usos dos mesmos, método de produção dos anticorpos multiespecíficos, biespecíficos ou monoclonais, kit, e moléculas biespecíficas semelhantes a anticorpo de três cadeias
BR122024019353A2 (pt)	2024-10-22	Anticorpos anti-pser413 tau, anticorpos humanizados, molécula de ácido nucleico, vetor ou plasmídeo, composições compreendendo os mesmos, células hospedeiras, métodos para preparação dos referidos anticorpos, uso dos mesmos e agente para tratar ou prevenir demência
EA040482B1 (ru)	2022-06-09	Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
EA048178B1 (ru)	2024-10-31	Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением